<DOC>
	<DOCNO>NCT01596530</DOCNO>
	<brief_summary>To compare activity AZD8931 placebo cell marker cancer tumour</brief_summary>
	<brief_title>Evaluation Drug Activity Women With Breast Cancer Previous Herceptin Treatment</brief_title>
	<detailed_description>A Randomised Double-Blind Placebo-controlled Multicentre Phase I Study Assess Biological Activity AZD8931 Patients Early Breast Cancer Ineligible Treatment trastuzumab define IHC status</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Females age 18 old Early stage breast cancer plan surgery Ineligible Trastuzumab ( Herceptin ) treatment per local guideline World health Organisation performance status 0 1 Tumour size amenable obtain adequate biopsy pre dose . Eligible Trastuzumab ( Herceptin ) Treatment Known sensitivity AZD8931 , excipients drug class ; Including oral tyrosine kinase inhibitor History eye condition e.g . previous injury within 3 month clinically significant eye disease Concurrent malignancy Unable discontinue medication herbal supplement know inhibit CYP3A4 CYP2D6</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Breast Neoplasm</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Breast Tumour</keyword>
	<keyword>Cancer Breast</keyword>
	<keyword>Cancer Breast</keyword>
</DOC>